DDInter1252 DDInter1676
Mycophenolic acid is a potent immunosuppressant agent that inhibits _de novo_ purine biosynthesis. It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative [azathioprine] due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity.[A249180,A249185] Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Mycophenolic acid {u} (Compound) resembles {v} (Compound) Mycophenolate mofetil
Mycophenolic acid {u} (Compound) treats {v} (Disease) systemic scleroderma
Mycophenolic acid {u} (Compound) binds {v} (Gene) IMPDH1
Mycophenolic acid {u} (Compound) upregulates {v} (Gene) UBE2L6
Mycophenolic acid {u} (Compound) downregulates {v} (Gene) SETD5
Mycophenolic acid {u} (Compound) causes {v} (Side Effect) Nervous system disorder
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ethotoin
Mycophenolic acid {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tigecycline
Mycophenolic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound)
Mycophenolic acid (Compound) treats systemic scleroderma (Disease)
Mycophenolic acid (Compound) binds IMPDH1 (Gene)
Mycophenolic acid (Compound) upregulates UBE2L6 (Gene)
Mycophenolic acid (Compound) downregulates SETD5 (Gene)
Mycophenolic acid (Compound) causes Nervous system disorder (Side Effect)
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Ethotoin
Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Tigecycline
Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans